Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Therapy 4B for Low Risk Multiple Myeloma
NCT00734877Phase 3Active, not recruiting
- Sponsor
- University of Arkansas
- Start
- Jul 2008
- Primary completion
- Sep 2027
- Modality
- Modified Peptides, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of melphalan, bortezomib, thalidomide, dexamethasone, cisplatin in multiple myeloma (MM), sponsored by University of Arkansas. Started Jul 2008; status: active, not recruiting.
02
Drugs
melphalanbortezomibthalidomidedexamethasonecisplatin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00734877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00734877.